Swipe om te navigeren naar een ander artikel
To derive a mapping algorithm to predict SF-6D utility scores from the non-preference-based LupusQoL and test the performance of the developed algorithm on a separate independent validation data set.
LupusQoL and SF-6D data were collected from 320 patients with systemic lupus erythematosus (SLE) attending routine rheumatology outpatient appointments at seven centres in the UK. Ordinary least squares (OLS) regression was used to estimate models of increasing complexity in order to predict individuals’ SF-6D utility scores from their responses to the LupusQoL questionnaire. Model performance was judged on predictive ability through the size and pattern of prediction errors generated. The performance of the selected model was externally validated on an independent data set containing 113 female SLE patients who had again completed both the LupusQoL and SF-36 questionnaires.
Four of the eight LupusQoL domains (physical health, pain, emotional health, and fatigue) were selected as dependent variables in the final model. Overall model fit was good, with R2 0.7219, MAE 0.0557, and RMSE 0.0706 when applied to the estimation data set, and R2 0.7431, MAE 0.0528, and RMSE 0.0663 when applied to the validation sample.
This study provides a method by which health state utility values can be estimated from patient responses to the non-preference-based LupusQoL, generalisable beyond the data set upon which it was estimated. Despite concerns over the use of OLS to develop mapping algorithms, we find this method to be suitable in this case due to the normality of the SF-6D data.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Guide to the methods of technology appraisal 2013 Foreword PMG9. (n.d.). Retrieved March 10, 2014, from http://publications.nice.org.uk/guide-to-the-methods-of-technology-appraisal-2013-pmg9
Sullivan, S., Lyles, A., Luce, B., & Grigar, J. (n.d.). AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in U.S. health plans and pharmacy benefits management organizations. Journal of Managed Care Pharmacy, 7(4), 272–282.
Canadian Agency for Drugs and Technologies in Health. (2006). Guidelines for the economic evaluation of health technologies. Canada. http://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf
Gold, M. R. (1996). Cost-effectiveness in health and medicine. New York: Oxford University Press.
McElhone, K., Abbott, J., Shelmerdine, J., Bruce, I. N., Ahmad, Y., Gordon, C., & Teh, L. S. (2007). Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis and Rheumatism, 57(6), 972–979. doi: 10.1002/art.22881. PubMedCrossRef
Clinical Trials - Corporate Translations. (n.d.). Retrieved February 7, 2014, from http://www.corptransinc.com/Sites/LupusQoL/Instrument-Information/Clinical-Trials.aspx
Ware, J. E., Snow, K. K., Kosinski, M., Gandek, B., & Institute NEMCHH. (1993). SF-36 health survey: Manual and interpretation guide. Boston, MA: The Health Institute, New England Medical Center.
Sanchez, M., McGwin, G., Duran, S., Fernandez, M., Reveille, J., Vila, L., & Alarcon, G. (2009). Factors predictive of overall health over the course of the disease in patients with systemic lupus erythematosus from the LUMINA cohort (LXII): Use of the SF-6D. Clinical and Experimental Rheumatology, 27, 64–71.
Harrison, M. J., Ahmad, Y., Haque, S., Dale, N., Teh, L.-S., Snowden, N., & Bruce, I. N. (2012). Construct and criterion validity of the short form-6D utility measure in patients with systemic lupus erythematosus. The Journal of Rheumatology, 39(4), 735–742. doi: 10.3899/jrheum.110648. PubMedCrossRef
Hochberg, M. C. (1997). Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism, 40(9), 1725. doi: 10.1002/1529-0131(199709)40:9&1725:AID-ART29&3.0.CO;2-Y. PubMedCrossRef
Ahmad, Y., & Bruce, I. (2004). Sunclinical atherosclerosis in systemic lupus erythematosus. The Journal of Rheumatology, 31, 841–843. PubMed
Pullenayegum, E. M., Tarride, J.-E., Xie, F., Goeree, R., Gerstein, H. C., & O’Reilly, D. (2010). Analysis of health utility data when some subjects attain the upper bound of 1: Are tobit and clad models appropriate? Value in Health, 13(4), 487–494. doi: 10.1111/j.1524-4733.2010.00695.x. PubMedCrossRef
Janssen, M. F., Pickard, A. S., Golicki, D., Gudex, C., Niewada, M., Scalone, L., & Busschbach, J. (2013). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: A multi-country study. Quality of Life Research, 22(7), 1717–1727. doi: 10.1007/s11136-012-0322-4. PubMedCentralPubMedCrossRef
Brazier, J., Connell, J., Papaioannou, D., Mukuria, C., Mulhern, B., Peasgood, T., Parry, G. (2014). A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. Health Technology Assessment doi: 10.3310/hta18340.
Cohen, J. (1988). Statistical power analysis for the behavioral sciences. UK: Psychology Press.
Harrison, M. J., Lunt, M., Verstappen, S. M., Watson, K. D., Bansback, N. J., & Symmons, D. P. (2010). Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis. Health and Quality of Life Outcomes, 8(1), 21. doi: 10.1186/1477-7525-8-21. PubMedCentralPubMedCrossRef
Gabriel, S., Drummond, M., Maetzel, A., Boers, M., Coyle, D., Welch, V., & Tugwell, P. (2003). OMERACT 6 Economics Working Group report: A proposal for a reference case for economic evaluation in rheumatoid arthritis. The Journal of Rheumatology, 30(4), 886–890. PubMed
Barton, G. R., Sach, T. H., Jenkinson, C., Avery, A. J., Doherty, M., & Muir, K. R. (2008). Do estimates of cost-utility based on the EQ-5D differ from those based on the mapping of utility scores? Health and Quality of Life Outcomes, 6(1), 51. doi: 10.1186/1477-7525-6-51. PubMedCentralPubMedCrossRef
Feeny, D., Spritzer, K., Hays, R. D., Liu, H., Ganiats, T. G., Kaplan, R. M., & Fryback, D. G. (2012). Agreement about identifying patients who change over time: Cautionary results in cataract and heart failure patients. Medical Decision Making, 32(2), 273–286. doi: 10.1177/0272989X11418671. PubMedCentralPubMedCrossRef
Kirwan, J. R., Boonen, A., Harrison, M. J., Hewlett, S. E., Wells, G. A., Singh, J. A., & Dworkin, R. H. (2011). OMERACT 10 patient perspective virtual Campus: Valuing health; measuring outcomes in rheumatoid arthritis fatigue, RA sleep, arthroplasty, and systemic sclerosis; and clinical significance of changes in health. The Journal of Rheumatology, 38(8), 1728–1734. doi: 10.3899/jrheum.110393. PubMedCrossRef
Ara, R., & Brazier, J. (2008). Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value in Health, 11(7), 1131–1143. doi: 10.1111/j.1524-4733.2008.00352.x. PubMedCrossRef
McELHONE, K., Castelino, M., Abbott, J., Bruce, I. N., Ahmad, Y., Shelmerdine, J., & Teh, L. S. (2010). The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus. The Journal of Rheumatology, 37(11), 2273–2279. doi: 10.3899/jrheum.091277. PubMedCrossRef
- Mapping the disease-specific LupusQoL to the SF-6D
- Springer International Publishing